Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11230526
SERIAL NO

16977828

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
JANSSEN PHARMACEUTICA NV2340 BEERSE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Lanter, James C Cambridge, US 44 304
Macielag, Mark J Gwynedd Valley, US 81 339
Sui, Zhihua Norristown, US 129 723
Wall, Mark Lansdale, US 32 325
Winters, Michael P Morgantown, US 8 44
Zhang, Yue-Mei Wellesley, US 61 458

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jul 25, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 25, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 25, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00